U.S. markets open in 39 minutes

DarioHealth Corp. (DRIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0700+0.0700 (+1.75%)
At close: 04:00PM EDT
4.2800 +0.21 (+5.16%)
Pre-Market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close4.0000
Bid3.8000 x 800
Ask4.3000 x 1100
Day's Range3.8000 - 4.1200
52 Week Range3.6600 - 19.3900
Avg. Volume222,749
Market Cap93.525M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-4.4680
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.39
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DRIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • DarioHealth Corp.
    Analyst Report: Stryker CorporationStryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Nearly one fourth of Stryker's total revenue currently comes from outside the United States.
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • PR Newswire

    DarioHealth Publishes New Clinical Research Linking the Use of its Biofeedback Device to Reduced Back Pain

    DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research examining the link between the use of Dario's biofeedback device to help users improve their posture and reduced back pain at the International Association of the Study of Pain (IASP) 2022 World Congress on Pain, being held in person in Toronto, Ontario from September 19th – 23rd and virtually.

  • PR Newswire

    DarioHealth Announces Two New Employer Contracts

    DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today two new employer contracts, including one for the full suite of integrated solutions. The new accounts are scheduled to launch in late 2022 and early 2023.

  • Zacks Small Cap Research

    DRIO: Suite Solution

    By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 15, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its second quarter 2022 operational and financial results in a press release and filed its Form 10-Q for the three-month period ending June 30, 2022. Dario hosted a conference call and webcast to discuss